Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.

Laplaud DA, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Lubetzki C, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Magy L, Defer G, Guennoc AM, Maubeuge N, Labeyrie C, Patry I, Nifle C, Casez O, Michel L, Rollot F, Leray E, Vukusic S, Foucher Y; SFSEP and OFSEP groups.

Neurology. 2019 Aug 13;93(7):e635-e646. doi: 10.1212/WNL.0000000000007938. Epub 2019 Jul 12.

PMID:
31300547
2.

Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort?

Mariani LL, Doulazmi M, Chaigneau V, Brefel-Courbon C, Carrière N, Danaila T, Defebvre L, Defer G, Dellapina E, Doé de Maindreville A, Geny C, Maltête D, Meissner WG, Rascol O, Thobois S, Torny F, Tranchant C, Vidailhet M, Corvol JC, Degos B; NS-Park/F-CRIN Network study group.

Parkinsonism Relat Disord. 2019 Apr 25. pii: S1353-8020(19)30207-X. doi: 10.1016/j.parkreldis.2019.04.012. [Epub ahead of print]

PMID:
31047798
3.

Outcomes and treatment management of a French cohort suffering from multiple sclerosis: A retrospective epidemiological study.

Defer G, de Seze J, Bouee S, Courouve L, Longin J, Payet M, Deleglise ASJ; study group.

Mult Scler Relat Disord. 2018 Oct;25:276-281. doi: 10.1016/j.msard.2018.08.004. Epub 2018 Aug 6.

PMID:
30170267
4.

Evidence of attentional impairments using virtual driving simulation in multiple sclerosis.

Harand C, Mondou A, Chevanne D, Bocca ML, Defer G.

Mult Scler Relat Disord. 2018 Oct;25:251-257. doi: 10.1016/j.msard.2018.08.005. Epub 2018 Aug 4.

PMID:
30144695
5.

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.

Tourbah A, Gout O, Vighetto A, Deburghgraeve V, Pelletier J, Papeix C, Lebrun-Frenay C, Labauge P, Brassat D, Toosy A, Laplaud DA, Outteryck O, Moreau T, Debouverie M, Clavelou P, Heinzlef O, De Sèze J, Defer G, Sedel F, Arndt C.

CNS Drugs. 2018 Jul;32(7):661-672. doi: 10.1007/s40263-018-0528-2.

6.

Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial.

Defer G, Le Caignec F, Fedrizzi S, Montastruc F, Chevanne D, Parienti JJ, Peyro-Saint-Paul L.

Trials. 2018 Mar 9;19(1):174. doi: 10.1186/s13063-018-2560-4.

7.

Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients.

Calocer F, Dejardin O, Droulon K, Launoy G, Defer G.

PLoS One. 2018 Feb 1;13(2):e0191646. doi: 10.1371/journal.pone.0191646. eCollection 2018.

8.

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaque, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.

Mult Scler Relat Disord. 2017 Nov;18:161-163. doi: 10.1016/j.msard.2017.08.009. Epub 2017 Aug 24. No abstract available.

PMID:
29141801
9.

Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.

Planche V, Moisset X, Morello R, Dumont E, Gibelin M, Charré-Morin J, Saubusse A, Mondou A, Reuter F, Defer G, Pelletier J, Brochet B, Clavelou P.

J Neurol Sci. 2017 Nov 15;382:148-154. doi: 10.1016/j.jns.2017.10.008. Epub 2017 Oct 6.

PMID:
29111011
10.

High-dose transdermal nicotine in Parkinson's disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study.

Villafane G, Thiriez C, Audureau E, Straczek C, Kerschen P, Cormier-Dequaire F, Van Der Gucht A, Gurruchaga JM, Quéré-Carne M, Evangelista E, Paul M, Defer G, Damier P, Remy P, Itti E, Fénelon G.

Eur J Neurol. 2018 Jan;25(1):120-127. doi: 10.1111/ene.13474. Epub 2017 Oct 23.

PMID:
28960663
11.

Prediction of disease activity in models of multiple sclerosis by molecular magnetic resonance imaging of P-selectin.

Fournier AP, Quenault A, Martinez de Lizarrondo S, Gauberti M, Defer G, Vivien D, Docagne F, Macrez R.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6116-6121. doi: 10.1073/pnas.1619424114. Epub 2017 May 22.

12.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks.

Neurology. 2016 Dec 6;87(23):2491-2494. Epub 2016 Nov 4. No abstract available.

PMID:
27815407
13.

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.

Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group.

Mult Scler. 2016 Nov;22(13):1719-1731. Epub 2016 Sep 1.

14.

[Reporting of harms in clinical trials: Vigilant support to the investigator. A guideline of REVISE' Group].

Marfin H, Fedrizzi S, Crépin S, Parienti JJ, Gimbert A, Blandamour V, Diallo A, Defer G, Bertram D, Peyro Saint Paul L; groupe REVISE.

Therapie. 2016 Oct;71(5):475-481. doi: 10.1016/j.therap.2016.05.007. Epub 2016 Jun 16. French.

PMID:
27423828
15.

Cutaneous and Mixed Nerve Silent Period Recordings in Symptomatic Paroxysmal Kinesigenic Dyskinesia.

Cogez J, Etard O, Derache N, Defer G.

Open Neurol J. 2016 May 26;10:9-14. doi: 10.2174/1874205X01610010009. eCollection 2016.

16.

Influence of education on cognitive performance and dopamine transporter binding in dementia with Lewy bodies.

Lamotte G, Morello R, Lebasnier A, Agostini D, Bouvard G, De La Sayette V, Defer GL.

Clin Neurol Neurosurg. 2016 Jul;146:138-43. doi: 10.1016/j.clineuro.2016.05.009. Epub 2016 May 10.

PMID:
27209028
17.

Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.

Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori É, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hautecoeur P, Tourbah A, Defer G.

J Neurol Sci. 2016 Apr 15;363:69-76. doi: 10.1016/j.jns.2016.02.012. Epub 2016 Feb 6.

PMID:
27000224
18.

The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis.

Branger P, Parienti JJ, Sormani MP, Defer G.

PLoS One. 2016 Mar 16;11(3):e0149685. doi: 10.1371/journal.pone.0149685. eCollection 2016.

19.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.

Neurology. 2016 Feb 23;86(8):771-8. doi: 10.1212/WNL.0000000000002395. Epub 2016 Jan 29.

20.

Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.

Peyro Saint Paul L, Debruyne D, Bernard D, Mock DM, Defer GL.

Expert Opin Drug Metab Toxicol. 2016;12(3):327-44. doi: 10.1517/17425255.2016.1136288. Epub 2016 Feb 17. Review.

PMID:
26699811
21.

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, de Sèze J, Zéphir H, Defer G, Lebrun-Frenay C, Moreau T, Clavelou P, Pelletier J, Berger E, Cabre P, Camdessanché JP, Kalson-Ray S, Confavreux C, Edan G.

PLoS One. 2015 Jul 6;10(7):e0132033. doi: 10.1371/journal.pone.0132033. eCollection 2015.

22.

Accuracy and cutoff values of delayed heart to mediastinum ratio with (123)I-metaiodobenzylguanidine cardiac scintigraphy for Lewy body disease diagnoses.

Lamotte G, Morello R, Lebasnier A, Agostini D, Defer GL.

BMC Neurol. 2015 May 15;15:83. doi: 10.1186/s12883-015-0338-9.

23.

Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.

Siri A, Carra-Dalliere C, Ayrignac X, Pelletier J, Audoin B, Pittion-Vouyovitch S, Debouverie M, Lionnet C, Viala F, Sablot D, Brassat D, Ouallet JC, Ruet A, Brochet B, Taillandier L, Bauchet L, Derache N, Defer G, Cabre P, de Seze J, Lebrun Frenay C, Cohen M, Labauge P.

J Neurol. 2015 Jul;262(7):1637-45. doi: 10.1007/s00415-015-7758-8. Epub 2015 May 1.

PMID:
25929666
24.

[Pierre Cesaro (1951–2013)].

Remy P, Defer G.

Rev Neurol (Paris). 2014 Dec;170(12):723-4. French. No abstract available.

PMID:
25632424
25.

Potential diagnostic value of regional myocardial adrenergic imaging using (123)I-MIBG SPECT to identify patients with Lewy body diseases.

Lebasnier A, Lamotte G, Manrique A, Peyronnet D, Bouvard G, Defer G, Agostini D.

Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1043-51. doi: 10.1007/s00259-015-2989-6. Epub 2015 Jan 28.

PMID:
25626701
26.

Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients.

Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, Denier C, Aubourg P, Bellesme C, Castelnovo G, Pelletier J, Audoin B, Kaphan E, de Seze J, Collongues N, Blanc F, Chanson JB, Magnin E, Berger E, Vukusic S, Durand-Dubief F, Camdessanche JP, Cohen M, Lebrun-Frenay C, Brassat D, Clanet M, Vermersch P, Zephir H, Outteryck O, Wiertlewski S, Laplaud DA, Ouallet JC, Brochet B, Goizet C, Debouverie M, Pittion S, Edan G, Deburghgraeve V, Le Page E, Verny C, Amati-Bonneau P, Bonneau D, Hannequin D, Guyant-Maréchal L, Derache N, Defer GL, Moreau T, Giroud M, Guennoc AM, Clavelou P, Taithe F, Mathis S, Neau JP, Magy L, Devoize JL, Bataillard M, Masliah-Planchon J, Dorboz I, Tournier-Lasserve E, Levade T, Boespflug Tanguy O, Labauge P.

Brain. 2015 Feb;138(Pt 2):284-92. doi: 10.1093/brain/awu353. Epub 2014 Dec 19.

PMID:
25527826
27.

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; Club Francophone de la Sclérose en Plaques Investigators.

JAMA Neurol. 2014 Apr;71(4):436-41. doi: 10.1001/jamaneurol.2013.6240.

PMID:
24566807
28.

No evidence for genetic association between glutamate transporter EAAT2 and Devic's neuromyelitis optica in caucasians and afro-caribbeans.

Hanoux V, Coulbault L, Derache N, Cabre P, De Seze J, Marignier R, Rudolf G, Emmanuelle Dugué A, Allouche S, Defer G; NOMADMUS Study Group.

Mult Scler Relat Disord. 2014 Jan;3(1):89-93. doi: 10.1016/j.msard.2013.06.012. Epub 2013 Jul 18.

PMID:
25877978
29.

Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.

Devos D, Moreau C, Maltête D, Lefaucheur R, Kreisler A, Eusebio A, Defer G, Ouk T, Azulay JP, Krystkowiak P, Witjas T, Delliaux M, Destée A, Duhamel A, Bordet R, Defebvre L, Dujardin K.

J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):668-74. doi: 10.1136/jnnp-2013-306439. Epub 2013 Nov 11.

PMID:
24218528
30.

Paraneoplastic opsoclonus myoclonus with autoantibodies to glutamic acid decarboxylase.

Lamotte G, Danaila TC, Jaillon-Rivière V, Hitier M, Defer GL.

Rev Neurol (Paris). 2014 Jan;170(1):50-1. doi: 10.1016/j.neurol.2013.03.010. Epub 2013 Oct 16. No abstract available.

PMID:
24139240
31.

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC), Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL.

Nat Genet. 2013 Nov;45(11):1353-60. doi: 10.1038/ng.2770. Epub 2013 Sep 29.

32.

Fatigue is associated with metabolic and density alterations of cortical and deep gray matter in Relapsing-Remitting-Multiple Sclerosis patients at the earlier stage of the disease: A PET/MR study.

Derache N, Grassiot B, Mézenge F, Emmanuelle Dugué A, Desgranges B, Constans JM, Defer GL.

Mult Scler Relat Disord. 2013 Oct;2(4):362-9. doi: 10.1016/j.msard.2013.03.005. Epub 2013 Apr 20.

PMID:
25877847
33.

Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice.

Keller A, Westenberger A, Sobrido MJ, García-Murias M, Domingo A, Sears RL, Lemos RR, Ordoñez-Ugalde A, Nicolas G, da Cunha JE, Rushing EJ, Hugelshofer M, Wurnig MC, Kaech A, Reimann R, Lohmann K, Dobričić V, Carracedo A, Petrović I, Miyasaki JM, Abakumova I, Mäe MA, Raschperger E, Zatz M, Zschiedrich K, Klepper J, Spiteri E, Prieto JM, Navas I, Preuss M, Dering C, Janković M, Paucar M, Svenningsson P, Saliminejad K, Khorshid HR, Novaković I, Aguzzi A, Boss A, Le Ber I, Defer G, Hannequin D, Kostić VS, Campion D, Geschwind DH, Coppola G, Betsholtz C, Klein C, Oliveira JR.

Nat Genet. 2013 Sep;45(9):1077-82. doi: 10.1038/ng.2723. Epub 2013 Aug 4.

PMID:
23913003
34.

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.

Outteryck O, Ongagna JC, Brochet B, Rumbach L, Lebrun-Frenay C, Debouverie M, Zéphir H, Ouallet JC, Berger E, Cohen M, Pittion S, Laplaud D, Wiertlewski S, Cabre P, Pelletier J, Rico A, Defer G, Derache N, Camu W, Thouvenot E, Moreau T, Fromont A, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Casez O, Hautecoeur P, Papeix C, Lubetzki C, Fontaine B, Couturier N, Bohossian N, Clanet M, Vermersch P, de Sèze J, Brassat D; BIONAT Network,; CFSEP.

Eur J Neurol. 2014;21(1):40-8. doi: 10.1111/ene.12204. Epub 2013 Jun 12.

PMID:
23895407
35.

Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier.

Krol S, Macrez R, Docagne F, Defer G, Laurent S, Rahman M, Hajipour MJ, Kehoe PG, Mahmoudi M.

Chem Rev. 2013 Mar 13;113(3):1877-903. doi: 10.1021/cr200472g. Epub 2012 Nov 19. Review. No abstract available.

PMID:
23157552
36.

Inflammatory-like presentation of CADASIL: a diagnostic challenge.

Collongues N, Derache N, Blanc F, Labauge P, de Seze J, Defer G.

BMC Neurol. 2012 Aug 21;12:78. doi: 10.1186/1471-2377-12-78.

37.

Relapsing polychondritis revealed by basal ganglia lesions.

Defer GL, Danaila T, Constans JM, Derache N.

Mov Disord. 2012 Aug;27(9):1094-6. doi: 10.1002/mds.23993. No abstract available.

PMID:
22865377
38.

Ultra-sensitive molecular MRI of cerebrovascular cell activation enables early detection of chronic central nervous system disorders.

Montagne A, Gauberti M, Macrez R, Jullienne A, Briens A, Raynaud JS, Louin G, Buisson A, Haelewyn B, Docagne F, Defer G, Vivien D, Maubert E.

Neuroimage. 2012 Nov 1;63(2):760-70. doi: 10.1016/j.neuroimage.2012.07.018. Epub 2012 Jul 17.

PMID:
22813950
39.

[Confusional state and disturbances of consciousness].

Bataille M, Defer GL.

Rev Prat. 2012 Feb;62(2):265-8. Review. French. No abstract available.

PMID:
22408880
40.

Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leucoencephalopathy (CADASIL) revealed by Claude's syndrome.

Le Doze F, Robert M, Apoil M, Wang A, Defer G.

Rev Neurol (Paris). 2012 Apr;168(4):384-6. doi: 10.1016/j.neurol.2011.08.017. Epub 2012 Mar 3. No abstract available.

PMID:
22385975
41.

CD49d expression as a promising biomarker to monitor natalizumab efficacy.

Defer G, Mariotte D, Derache N, Toutirais O, Legros H, Cauquelin B, Le Mauff B.

J Neurol Sci. 2012 Mar 15;314(1-2):138-42. doi: 10.1016/j.jns.2011.10.005. Epub 2011 Nov 1.

PMID:
22050952
42.

Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence.

Vivien D, Gauberti M, Montagne A, Defer G, Touzé E.

J Cereb Blood Flow Metab. 2011 Nov;31(11):2119-34. doi: 10.1038/jcbfm.2011.127. Epub 2011 Aug 31. Review.

43.

Preclinical evidence toward the use of ketamine for recombinant tissue-type plasminogen activator-mediated thrombolysis under anesthesia or sedation.

Gakuba C, Gauberti M, Mazighi M, Defer G, Hanouz JL, Vivien D.

Stroke. 2011 Oct;42(10):2947-9. doi: 10.1161/STROKEAHA.111.620468. Epub 2011 Aug 4.

PMID:
21817137
44.
45.

Stroke and the immune system: from pathophysiology to new therapeutic strategies.

Macrez R, Ali C, Toutirais O, Le Mauff B, Defer G, Dirnagl U, Vivien D.

Lancet Neurol. 2011 May;10(5):471-80. doi: 10.1016/S1474-4422(11)70066-7. Review.

PMID:
21511199
46.

Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility.

Couturier N, Bucciarelli F, Nurtdinov RN, Debouverie M, Lebrun-Frenay C, Defer G, Moreau T, Confavreux C, Vukusic S, Cournu-Rebeix I, Goertsches RH, Zettl UK, Comabella M, Montalban X, Rieckmann P, Weber F, Müller-Myhsok B, Edan G, Fontaine B, Mars LT, Saoudi A, Oksenberg JR, Clanet M, Liblau RS, Brassat D.

Brain. 2011 Mar;134(Pt 3):693-703. doi: 10.1093/brain/awr010.

PMID:
21354972
47.

Cancer and multiple sclerosis in the era of disease-modifying treatments.

Lebrun C, Vermersch P, Brassat D, Defer G, Rumbach L, Clavelou P, Debouverie M, de Seze J, Wiertlevsky S, Heinzlef O, Tourbah A, Fromont A, Frenay M.

J Neurol. 2011 Jul;258(7):1304-11. doi: 10.1007/s00415-011-5929-9. Epub 2011 Feb 4.

PMID:
21293872
48.

High-risk syndrome for neuromyelitis optica: a descriptive and comparative study.

Collongues N, Marignier R, Zéphir H, Blanc F, Vukusic S, Outteryck O, Fleury M, Ruet A, Borgel F, Thouvenot E, Moreau T, Defer G, Derache N, Pelletier J, Audoin B, Debouverie M, Labauge P, Gout O, Camu W, Brassat D, Brochet B, Vermersch P, Confavreux C, de Seze J.

Mult Scler. 2011 Jun;17(6):720-4. doi: 10.1177/1352458510396923. Epub 2011 Jan 14.

PMID:
21239412
49.

[Cognitive rehabilitation in multiple sclerosis: a review of the literature].

Brissart H, Daniel F, Morele E, Leroy M, Debouverie M, Defer GL.

Rev Neurol (Paris). 2011 Apr;167(4):280-90. doi: 10.1016/j.neurol.2010.07.039. Epub 2010 Dec 21. Review. French.

PMID:
21176930
50.

[The default mode network: cognitive role and pathological disturbances].

Mevel K, Grassiot B, Chételat G, Defer G, Desgranges B, Eustache F.

Rev Neurol (Paris). 2010 Nov;166(11):859-72. doi: 10.1016/j.neurol.2010.01.008. Epub 2010 Mar 11. Review. French.

Supplemental Content

Support Center